MONTREAL, QUEBEC--(Marketwired - June 16, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the
"Company") announced today that each director nominee listed in the Management Information Circular dated May 13, 2016 was
elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec.
The details of the election are as follows:
| DIRECTOR NOMINEE |
OUTCOME |
VOTES FOR |
% FOR |
VOTES WITHHELD |
% WITHHELD |
| James C. Gale |
Elected |
71,554,988 |
99.11% |
640,829 |
0.89% |
| Jonathan Ross Goodman |
Elected |
72,146,127 |
99.93% |
49,690 |
0.07% |
| Meir Jakobsohn |
Elected |
72,138,037 |
99.92% |
57,780 |
0.08% |
| Robert N. Lande |
Elected |
71,556,188 |
99.11% |
639,629 |
0.89% |
| Ed Schutter |
Elected |
72,067,904 |
99.82% |
127,913 |
0.18% |
| Sylvie Tendler |
Elected |
72,041,935 |
99.79% |
153,882 |
0.21% |
The results of the final votes regarding all matters subject to a vote during the Annual Meeting will be made available on
SEDAR (www.sedar.com).
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or
in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s
shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web
site at www.gud-knight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking
statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these
forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these
assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current
expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form
for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information or future events, except as required by law.